Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ligand Avinza Reimbursement Expected By PBMs Covering 150-200 Mil. Lives

Executive Summary

Ligand expects to enter agreements for the opioid Avinza with pharmacy benefit managers covering a total of 150 mil. to 200 mil. lives within the next several months, Ligand CEO Dave Robinson said during an Aug. 13 quarterly call

You may also be interested in...



From The Quarterly Conference Calls

Geneva Augmentin generic reserve: Geneva's generic amoxicillin/clavulanate earnings are being placed in a reserve in the event the company loses GlaxoSmithKline's appeal of the Augmentin patent lawsuit, Novartis CEO Daniel Vasella said July 22. "We will book sales, but we will not book the earnings out of this product but put them in a reserve," the exec said. "The additional exposure should we - against all odds - lose the appeal next year, would be an amount which we can digest, I would say, rather easily." GSK is appealing a May 22 ruling in Geneva's favor; a decision could come as early as January (1"The Pink Sheet" May 27, p. 20). Geneva launched amoxicillin generics in June...

Ligand Avinza launch

Ligand's Avinza price will range from $231 for 100 30 mg capsules to $790 for 100 120 mg capsules, according to Red Book data. Distribution of extended release morphine is expected to begin in May, with availability broadening for 12 to 18 months post-launch. Promotion will commence in late May or early June; Ligand completed the hiring of its 80-rep sales force in April. Avinza was approved by FDA March 20 (1"The Pink Sheet" March 25, p. 23)...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS040373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel